Sequence 3 from Patent US 20020137896

General Information


DRACP ID  DRACP01222

Peptide Name   Sequence 3 from Patent US 20020137896

Sequence  PIRLSKEKINDLLQRSQGDLTSSQHEIVH

Sequence Length  29

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01222

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C143H241N45O47

Absent amino acids  ACFMWY

Common amino acids  LS

Mass  384238

Pl  7.71

Basic residues  6

Acidic residues  4

Hydrophobic residues  8

Net charge  2

Boman Index  -8133

Hydrophobicity  -83.45

Aliphatic Index  104.14

Half Life 
  Mammalian: 1.4 hour
  Yeast: 3 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  7

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2002/0137896 A1

Patent Title  Antitumor protein and gene encoding same.

Other Iinformation  Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status: Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004

Other Published ID  US6291648  US6762296 




DRACP is developed by Dr.Zheng's team.